Necroptotic signaling is primed in Mycobacterium tuberculosis-infected macrophages, but its pathophysiological consequence in disease is restricted

Michael D Stutz; Samar Ojaimi; Cody Allison; Simon Preston; Philip Arandjelovic; Joanne M Hildebrand; Jarrod J Sandow; Andrew I Webb; John Silke; Warren S Alexander; Marc Pellegrini

Journal article

Necroptotic signaling is primed in Mycobacterium tuberculosis-infected macrophages, but its pathophysiological consequence in disease is restricted

Michael D Stutz, Samar Ojaimi, Cody Allison, Simon Preston, Philip Arandjelovic, Joanne M Hildebrand, Jarrod J Sandow, Andrew I Webb, John Silke, Warren S Alexander, Marc Pellegrini

Cell Death & Differentiation | NATURE PUBLISHING GROUP | Published : 2018

DOI: 10.1038/s41418-017-0031-1

University of Melbourne Researchers

Andrew Webb Author Medical Biology (W.E.H.I.)

Cody Allison Author Medical Biology (W.E.H.I.)

Jarrod Sandow Author Medical Biology (W.E.H.I.)

John Silke Author Medical Biology (W.E.H.I.)

Joanne Hildebrand Author Medical Biology (W.E.H.I.)

Grants

Awarded by National Health and Medical Research Council Australia

Funding Acknowledgements

We thank James Vince, James Murphy and Najoua Lalaoui for discussions, Lachlan Whitehead and the Centre for Dynamic Imaging for assistance with image analysis, Benjamin Kile for supplying Ifnar1<SUP>-/-</SUP> mice, the Australian Red Cross Blood Service for supplying buffy packs and Liana Mackiewicz for technical support. This work was supported by National Health and Medical Research Council Australia (Grants 1006592, 1045549 and 1065626 to MP, 1039014 to SP, 1056282 to SO, 1016647 and 1058344 to WSA, and 1057905 and 1058190 to JS), The Sylvia & Charles Viertel Senior Medical Research Fellowship (M. P.), the Victorian State Government Operational Infrastructure Support and the Independent Research Institutes Infrastructure Support Scheme of the Australian Government National Health and Medical Research Council. The Walter and Eliza Hall Institute of Medical Research have a research license agreement with TetraLogic Pharmaceuticals (Malvern, PA, USA), the manufactures of the cIAP antagonist birinapant. MP and JS provided consultative advice to, and were on the scientific advisory board of, TetraLogic Pharmaceuticals.